早期益生菌补充预防湿疹与哮喘:一项随机对照试验
该随机双盲对照试验在高风险婴儿中评估生命最初6个月补充鼠李糖乳杆菌GG(LGG)对湿疹(主要终点)及哮喘和鼻炎(次要终点)累积发病率的影响。结论认为,高风险婴儿早期补充LGG6个月似乎不能预防2岁时湿疹或哮喘的发生。
要点
- 高风险婴儿出生后6个月每日补充LGG并未显著降低2岁时湿疹累积发病率。
- 5岁时哮喘累积发病率两组差异无统计学意义。
- 该研究不支持对高风险婴儿常规早期补充LGG以预防湿疹或哮喘。
核心结论
- 对于高风险婴儿,生命最初6个月早期补充LGG似乎不能预防2岁时湿疹或哮喘的发生。
研究设计与样本
- 研究对象为高风险婴儿,主要终点为湿疹累积发病率,次要终点为哮喘和鼻炎。
- 采用生存分析方法估计疾病发病率及LGG延迟或预防疾病的效力。
- 婴儿招募历时6年,中位随访4.6年,2年保留率95%。
临床怎么用
- 对于高风险婴儿,不应基于预防湿疹或哮喘的目的常规推荐早期补充LGG。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine if probiotic administration during the first 6 months of life decreases childhood asthma and eczema. METHODS: We conducted a randomized, double-blind controlled trial of Lactobacillus rhamnosus GG (LGG) supplementation on the cumulative incidence of eczema (primary end point) and asthma and rhinitis (secondary end points) in high-risk infants. For the first 6 months of life, intervention infants (n = 92) received a daily dose of 10 billion colony-forming units of LGG and 225 mg of inulin (Amerifit Brands, Cromwell, CT), and control infants (n = 92) received 325 mg of inulin alone. We used survival analysis methods to estimate disease incidences in the presence or absence of LGG and to estimate the efficacy of LGG in delaying or preventing these diseases. RESULTS: Infants were accrued over a 6-year period (median follow-up: 4.6 years; 95% retention rate at 2 years). At 2 years of age, the estimated cumulative incidence of eczema was 30.9% (95% confidence interval [CI], 21.4%-40.4%) in the control arm and 28.7% (95% CI, 19.4%-38.0%) in the LGG arm, for a hazard ratio of 0.95 (95% CI, 0.59-1.53) (log-rank P = .83). At 5 years of age, the cumulative incidence of asthma was 17.4% (95% CI, 7.6%-27.1%) in the control arm and 9.7% (95% CI, 2.7%-16.6%) in the LGG arm, for a hazard ratio of 0.88 (95% CI, 0.41-1.87) (log-rank P = .25). CONCLUSIONS: For high-risk infants, early LGG supplementation for the first 6 months of life does not appear to prevent the development of eczema or asthma at 2 years of age.
引用
- Cabana MD, McKean M, Caughey AB, et al. Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial. Pediatrics. 2017. PMID: 28784701. doi:10.1542/peds.2016-3000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。